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http://dx.doi.org/10.1016/j.ccr.2013.09.004SUMMARYEGFRvIII, a frequently occurring mutation in primary glioblastoma, results in a protein product that cannot
bind ligand, but signals constitutively. Deducing how EGFRvIII causes transformation has been difficult
because of autocrine and paracrine loops triggered by EGFRvIII alone or in heterodimers with wild-type
EGFR. Here, we document coexpression of EGFR and EGFRvIII in primary human glioblastoma that drives
transformation and tumorigenesis in a cell-intrinsic manner. We demonstrate enhancement of downstream
STAT signaling triggered by EGFR-catalyzed phosphorylation of EGFRvIII, implicating EGFRvIII as a sub-
strate for EGFR. Subsequent phosphorylation of STAT3 requires nuclear entry of EGFRvIII and formation
of an EGFRvIII-STAT3 nuclear complex. Our findings clarify specific oncogenic signaling relationships be-
tween EGFR and EGFRvIII in glioblastoma.INTRODUCTION
The epidermal growth factor receptor (EGFR) plays a prominent
role inmany tumors includingglioblastoma, themostcommonpri-
marybrain tumor.Amplificationandoverexpression isobserved in
> 50%of glioblastoma.Half ofEGFR-amplified tumors in turn har-
bor the EGFRvIIImutant, an intragenic rearrangement generated
by in-frame deletion of exons 2–7 from this receptor tyrosine ki-
nase (RTK), which consequently signals constitutively in the
absence of ligand (Huang et al., 1997; Sugawa et al., 1990;Significance
EGFR is commonly amplified and mutated in primary glioblas
observed mutant variant, EGFRvIII, signals via potential autoc
target this complex signaling has contributed to failed clinical
coexpression of EGFR and EGFRvIII in human tumors, identify
demonstrate that EGFR and EGFRvIII cooperate to phosphor
findings elucidate signaling interactions between EGFR and E
EGFRvIII-STAT axis as a therapeutic approach to treat EGFRv
438 Cancer Cell 24, 438–449, October 14, 2013 ª2013 Elsevier Inc.Wong et al., 1992). A number of studies noted that amplification
andoverexpressionofbothEGFRandEGFRvIIIconferredaworse
prognosis in glioma patients (Heimberger et al., 2005; Shinojima
et al., 2003), with a clinical trial suggesting vaccination against
EGFRvIII as a promising immunotherapy (Sampson et al., 2010).
In contrast, a recent report failed to associate amplification of
EGFR with outcome (Weller et al., 2009). Expression of EGFRvIII
in glioblastoma is heterogeneous and is usually observed in a sub-
population of neoplastic cells (Nishikawa et al., 2004). Most anti-
bodies against EGFR and EGFRvIII cross-react, complicatingtoma, a highly malignant brain tumor. The most commonly
rine and paracrine loops. Our inability to fully elucidate and
trials in patients with few options for therapy. We document
a cell-intrinsic role for coexpression in vitro and in vivo, and
ylate STAT proteins, promoting malignant progression. Our
GFRvIII and suggest combinatorial targeting of the EGFR-
III mutant glioblastoma.
Figure 1. Detection of EGFR and EGFRvIII in
Primary Human Glioblastoma
(A) Graphical analysis of immunohistochemical
data from Table S1 is shown.
(B and C) Immunohistochemical staining of a pri-
mary human GBM with EGFR-specific (top panel)
or EGFRvIII-specific antibody (bottom panel) on
consecutive sections (brown, diaminobenzidine;
light blue, nuclear counterstain with hemalum) is
shown. Black scale bar corresponds to 50 mm. (C)
Immunofluorescence double-staining of primary
GBM tissue sections using EGFR-specific and
EGFRvIII-specific antibodies is shown. Cells dou-
ble-positive for both EGFR-WT and EGFRvIII are
indicated by arrows. An enlarged image of the re-
gion marked with a white square (upper-left panel
in C) is shown on the right side. Lower panels
demonstrate EGFR-WT/EGFRvIII-positive tumor
cells in two additional distinct tumors; green fluo-
rescence, EGFR-WT; red fluorescence, EGFRvIII;
blue fluorescence, nuclei (40,6-diamidino-2-phe-
nylindole). White scale bar corresponds to 10 mm.
Staining in (A) used pan EGFR antibody (Ventana
790-2988, clone 3C6) and EGFRvIII antibody (Duke
University, L8A4). Staining in (B) and (C) usedEGFR
antibody (Dako DAK-H1-WT) and EGFRvIII anti-
body (Celldex polyclonal rabbit antiserum 6549).
See also Figure S1 and Table S1.
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Cooperation between EGFR and EGFRvIII in Gliomaefforts to examine specific coexpression of EGFR or EGFRvIII in
individual tumor cells within a glioblastoma.
Does crosstalk occur between EGFR and EGFRvIII signaling?
EGFRvIII induces heparin-binding EGF (HB-EGF) in glioma cells.
A neutralizing antibody to HB-EGF blocked EGFRvIII-induced pro-
liferation, raising the possibility of an EGFRvIII–HB-EGF–EGFR au-
tocrine loop in glioblastoma (Inda et al., 2010; Ramnarain et al.,
2006). Expression of EGFRvIII also induces secretion of inter-
leukin-6 and leukemia inhibitory factor. These cytokines activate
gp130, generating a paracrine loop that promotes activation of
EGFR in neighboring cells (Inda et al., 2010). Physical interaction
of EGFRvIII withEGFRhasadditionally been proposed, associated
with phosphorylation of both EGFRvIII and EGFR (Luwor et al.,
2004). Collectively, these studies suggest paracrine interactions
between cells expressingEGFRor EGFRvIII, aswell as physical in-
teractions between EGFRvIII and EGFR within individual cells, as
contributors to progression in glioma. Here, we analyze coexpres-
sionofEGFRandEGFRvIII inprimaryglioblastomatumorcells from
patients and elucidate functional implications of these findings.
RESULTS
Coexpression of EGFR and EGFRvIII in Human
Glioblastoma
Our study demonstrates by immunohistochemistry the expres-
sion status of EGFR and EGFRvIII across a series of human pri-
mary glioblastoma tissues (Figure 1A; Table S1 available online).Cancer Cell 24, 438–449Among 58 tumors, 83% (48 of 58) stained
for EGFR. Of these, 11 (19% of the total)
were positive for EGFRvIII, with all
EGFRvIII-positive tumors also expressing
EGFR. Although these data require thatwe subtract the EGFRvIII staining from the EGFR/EGFRvIII cos-
tained samples (a relatively imprecise process), these data are
nevertheless consistent with findings by others (Biernat et al.,
2004) and suggest that expression of EGFRvIII typically occurs
in glioblastoma tumors that also overexpress EGFR.Representa-
tive immunostaining is shown (Figures S1A–S1F).
The EGFR antibody used in Figure 1A, Figures S1A–S1F, and
Table S1 recognizes both full-length EGFR and EGFRvIII. There-
fore, double-immunofluorescence staining experiments were
performed using EGFR- and EGFRvIII-specific antibodies. We
assessed coexpression of EGFR and EGFRvIII in individual
tumor cells in glioblastoma tissue sections from 10 cases previ-
ously shown by immunohistochemistry to be positive for both
proteins. Representative immunostaining is shown (Figure 1B).
Antibody specificity is shown in Figure S1G. The majority of cells
within tumors coexpressing EGFR and EGFRvIII showed expres-
sion of a single RTK. In each sample, however, individual tumor
cells or groups of tumor cells were detected that overexpressed
both proteins, with EGFR and EGFRvIII colocalized in tumor cells
(Figure 1C). These results indicate that EGFR and EGFRvIII are
jointly overexpressed within subsets of tumor cells in human pri-
mary glioblastoma tissue.
EGFR and EGFRvIII Cooperate to Promote Tumor
Growth In Vitro and In Vivo
Both EGFR and EGFRvIII amplicons are rapidly lost upon
culturing primary glioblastoma tumors (Pandita et al., 2004). To, October 14, 2013 ª2013 Elsevier Inc. 439
Figure 2. Coexpression of EGFR and EGFR-
vIII Enhances Malignancy
(A and B) Anchorage-independent growth of LN-
229:parent, LN-229:EGFR, LN-229:EGFRvIII, or
LN-229:EGFR/EGFRvIII cells was measured by
colony formation in soft agar, in the presence or
absence of EGF (50 ng/ml). (A) Representative
colonies were photographed after 3 weeks. Scale
bar corresponds to 50 mm. (B) The number of
colonies on 6-well plates in triplicate, normalized
to parental cells without EGF, was quantified after
3 weeks. Data are presented as mean ± SE
obtained from three 6-well plates. **p < 0.05; ***p <
0.0001.
(C and D) LN-229:parent, LN-229:EGFR, LN-
229:EGFRvIII, and LN-229:EGFR/EGFRvIII cells
(106) were injected subcutaneously and separately
in BALB/c nu/nu animals, 5 mice/group. (C)
Representative tumors after 6 weeks are shown.
Scale bar corresponds to 10 mm. (D) Each point
represents mean tumor volume ± SE obtained
from five mice.
See also Figure S2.
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Cooperation between EGFR and EGFRvIII in Gliomarecapitulate coexpression, we therefore transduced EGFR,
EGFRvIII, or both in human glioma cell lines LN-229 and
U87MG. Because endogenous EGFR is expressed at low levels
in these lines, we also examined mouse NIH 3T3 fibroblast cells,
which show little to no expression of EGFR (Bishayee et al.,
1999). EGFR and EGFRvIII cooperated in transformation, form-
ing both significantly more and larger colonies, as compared
with parent, EGFR, or EGFRvIII, when expressed in LN-229 cells
in the absence of EGF (Figures 2A and 2B; p < 0.0001 by
Student’s t test—281% increase in colony number with LN-
229:EGFR/EGFRvIII versus LN-229:parent cells; p = 0.0003 by
Student’s t test—234% increase for LN-229:EGFR/EGFRvIII
versus LN-229:EGFR cells; and p = 0.0011 by Student’s
t test—145% increase for LN-229:EGFR/EGFRvIII versus LN-
229:EGFRvIII cells). Addition of EGF led to increased colony
numbers in LN-229:EGFR/EGFRvIII cells (p = 0.0083 by
Student’s t test—139% increase in the presence EGF when
compared with absence of EGF) with little effect on cells
expressing vector, EGFR, or EGFRvIII alone. LN-229:EGFR/
EGFRvIII cells were transformed to modest levels without EGF
treatment, perhaps because of EGFR ligands present in the fetal
calf serum used in this assay (Figures 2A and 2B). Similar results
were obtained in U87MG cells (Figure S2). Importantly, to
exclude the possibility that increased transformation was related
to doubling of total levels of EGFR/EGFRvIII kinase activity, we
also analyzed untransformed NIH 3T3 cells. In these cells (Fig-
ure S2), EGFR and EGFRvIII synergize in transformation, sug-
gesting a greater than additive effect. Similar results were
observed for LN-229 cells in vivo, where EGFR and EGFRvIII
led to greater-than-additive effects (compared to LN-
229:EGFR or LN-229:EGFRvIII cells) in driving tumor size (Fig-
ures 2C and 2D).
To further evaluate the oncogenic potential of cells coexpress-
ing EGFR and EGFRvIII in vivo, we established xenografts from
cell lines in Figures 2A and 2B. Growth of EGFR/EGFRvIII tumor
xenografts was increased markedly (Figures 2C and 2D) as
compared with tumors driven by parent, EGFR, or EGFRvIII
(p = 0.0003, Student’s t test—198% increase in LN-229:EGFR/440 Cancer Cell 24, 438–449, October 14, 2013 ª2013 Elsevier Inc.EGFRvIII cells compared with LN-229:parent cells; p = 0.0005,
Student’s t test—82% increase when compared with LN-
229:EGFR cells; and p = 0.0028, Student’s t test—31% increase
when compared with LN-229:EGFRvIII cells).
Coexpression of EGFR and EGFRvIII Phosphorylates
STAT Proteins In Vitro and In Vivo
No significant differences were observed in the abundance of
phosphorylated AKT (p-AKT) and p-ERK among EGF-treated
LN-229:EGFR/EGFRvIII, LN-229:EGFR, and LN-229:EGFRvIII
lines (Figure 3A). STAT signals downstream of EGFR are acti-
vated in 60% of glioblastoma patients, drives progression in
animal models of glioma, and correlates inversely with survival
(Birner et al., 2010; Darnell et al., 1994; Doucette et al., 2012;
Shao et al., 2003), prompting us to analyze this pathway. Addi-
tion of EGF led to a statistically significant increase in the abun-
dance of p-STAT3 and p-STAT5 in EGFR/EGFRvIII cells, as
compared with parent, EGFR, and EGFRvIII cells (Figure 3A; Fig-
ure S3). Induction of p-STAT3 and p-STAT5 in cells coexpressing
EGFR/EGFRvIII was also observed in U87MG human glioma and
mouse fibroblast NIH 3T3 cells (Figure S3). Higher levels of
p-STAT3 and p-STAT5 were also observed in xenografted tu-
mors from LN-229:EGFR/EGFRvIII cells, as compared with
parent, EGFR, or EGFRvIII tumors (Figure 3A). Interestingly,
although levels of p-STAT3 and p-STAT5 were very low in
cultured LN-229:EGFRvIII cells, both STAT3 and STAT5 were
phosphorylated to a moderate degree in xenografted EGFRvIII
tumors (perhaps because of re-expression of EGFR) albeit to
lower levels than observed in EGFR/EGFRvIII tumors (Figure 3A).
We evaluated whether STAT signaling correlated with coex-
pression of EGFR and EGFRvIII in human tumors. Analysis of
58 human glioblastoma tumors demonstrated that expression
of EGFRvIII was limited to tumors that expressed EGFR (Fig-
ure 1A; Table S1). We therefore further analyzed primary human
glioblastoma tumors negative for expression of both EGFR and
EGFRvIII, positive for EGFR alone, or positive for both EGFR
and EGFRvIII. Figure 3B demonstrates that p-STAT3 was ex-
pressed at highest levels in primary human tumors that
Figure 3. Coexpression of EGFR and EGFRvIII Is Associated with Phosphorylation of STAT Proteins
(A) LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, or LN-229:EGFR/EGFRvIII cells were serum-starved for 24 hr and then treatedwith or without EGF (50 ng/ml)
for 15 min prior to harvest, lysis, and analysis by immunoblot using the antisera indicated (left panels). This same panel of cells (106) was injected subcutaneously
in BALB/c nu/numice, and animals were sacrificed after 6weeks. Two representative tumors in each groupwere lysed and analyzed by immunoblot (right panels).
(B) Control (autopsy specimen) or human GBMs from the Brain Tumor Research Center at UCSF were lysed and analyzed by immunoblot with the antisera
indicated. EGFRandEGFRvIII statuswere preconfirmedby immunohistochemical staining. Sampleswere lysedand immunoblotted. InEGFR immunoblot, the top
band (arrow) has mobility of wild-type EGFR, whereas the lower band (arrowhead) has mobility of EGFRvIII. The intensity of p-STAT3, quantified by densitometry
using Silver Fast Scanner and ImageJ software, is shown below each immunoblot as fold increase relative to normal brain, normalized to GAPDH (bottom panel).
(C and D) Immunohistochemical staining of adjacent sections (left) and immunofluorescent costaining of primary glioblastoma tissue using EGFR, EGFRvIII, and p-
STAT3 (Tyr705;mousemonoclonal antibody3E2;Cell Signaling)-specificantibodies (right) areshown.Arrows indicatepositionof the nucleusand identify tumorcells
positive for both EGFR (green) and p-STAT3 (red) or for both EGFRvIII (green) and p-STAT3 (red). Black scale bar corresponds to 100 mm, and white bar to 10 mm.
See also Figure S3.
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Cooperation between EGFR and EGFRvIII in Gliomacoexpressed EGFR and EGFRvIII and at lower levels in tumors
that expressed either EGFR alone or neither kinase. Analysis of
nine additional human glioblastoma tumors demonstrated gen-
eral alignment among levels of EGFR, EGFRvIII, and p-STAT
proteins (Figures S3E– S3G). Immunohistochemical staining of
10 EGFR/EGFRvIII-positive primary human glioblastoma tissue
sections demonstrated subsets of tumors cells with strong nu-
clear expression of p-STAT3 that overlapped regionally with
both EGFR and EGFRvIII in every case (representative staining
shown in Figure 3C), with immunofluorescence suggesting
some nuclear or perinuclear expression of EGFRvIII (Figure S3H)
and colocalization of p-STAT3 with EGFRvIII or with EGFRwithin
individual cells (Figure 3D).
We next examined the kinetics through which EGFR and
EGFRvIII could enhance STAT signaling. EGF treatment of LN-
229:EGFR/EGFRvIII cells led to prolonged phosphorylation of
both EGFR and EGFRvIII, starting at 15 min, continuing through
60min, and correlating with sustained phosphorylation of STAT3
and STAT5 (Figure 4A). In contrast, phosphorylation of EGFR in
LN-229:EGFR cells peaked at 30 min, and then declined
more rapidly, with less robust peak and temporal phosphory-
lation of STAT signaling. In LN-229:parent and LN-229:
EGFRvIII cells, EGF treatment had little effect on phosphoryla-
tion of EGFRvIII, STAT3, or STAT5. Using the protein synthesis
inhibitor cycloheximide, we showed similar half-lives for EGFR,
EGFRvIII, and STAT3 proteins in LN-229:EGFR/EGFRvIII cells,
as compared with parent, EGFR, and EGFRvIII cells (Figure 4B),
indicating that prolonged temporal phosphorylation of STAT3
in LN-229:EGFR/EGFRvIII cells was independent of receptors
and STAT3 stability. These data suggest that EGFR and
EGFRvIII coordinately drive enhanced and prolonged STAT
phosphorylation.
To address biological effects of EGFRvIII-STAT signaling in
human tumors, we queried TCGA data for key expression differ-
ences in EGFR/EGFRvIII-coamplified tumors, comparing these
to tumors with amplification of EGFR in the absence of EGFRvIII.
These data (Figure S4) demonstrate 33 genes that were differen-
tially expressed between the EGFR-EGFRVIII and EGFR-ampli-
fied samples. Of note, these genes converge on PKC and PLC,
both of which have been previously demonstrated to interact
with STAT3 (Lo et al., 2010; McBeth et al., 2013; Parsons
et al., 2013).
EGFR Phosphorylates vIII, Cooperating in
Transformation
Surprisingly, the abundance of phosphorylated EGFRvIII was
strongly increased when LN-229:EGFR/EGFRvIII cells were
treated with EGF (Figure 3A), evident at Y1068 and Y1173 tyro-
sine residues (Figure S3). EGFRvIII is unable to bind ligand and
demonstrates constitutive albeit low activity, whereas EGFR
shows ligand-dependent signaling. Accordingly, EGF-induced
phosphorylation of EGFRvIII in LN-229:EGFR/EGFRvIII cells
suggests that EGFR cross-phosphorylates EGFRvIII in response
to EGF.
To explore mechanisms through which EGFR could phos-
phorylate EGFRvIII, we tested analog-sensitive (as) alleles of
EGFR, engineered to accept analogs of ATP not efficiently
used by wild-type kinases (Bishop et al., 2000; Blair et al.,
2007). NIH 3T3 cells, which have low or undetectable levels of442 Cancer Cell 24, 438–449, October 14, 2013 ª2013 Elsevier Inc.endogenous EGFR (Bishayee et al., 1999), were stably trans-
duced either with wild-type or analog-sensitive alleles of EGFR
(EGFRas3) or EGFRvIII (vIIIas3), individually and in combination.
Cells transduced with EGFRas3 demonstrated EGF-dependent
phosphorylation of EGFRas3; whereas cells transduced with
EGFRvIIIas3 showed baseline phosphorylation of vIIIas3, sug-
gesting retention of basal and EGF-driven kinase activities (Fig-
ures 5A and 5B). Treatment with the bulky covalent ATP-analog
4TB [N-(4-(4-tert-butylphenylamino)quinazolin-6-yl)acrylamide
(Blair et al., 2007)] blocked phosphorylation of EGFRas3,
EGFRvIIIas3, and downstream targets. Under the same condi-
tions, as expected, 4TB had no effect on phosphorylation of
downstream signaling in cells transduced with either wild-type
EGFR or EGFRvIII.
Having confirmed that EGFRas3 and EGFRvIIIas3 could be
blocked by 4TB, we next analyzed transphosphorylation. In
EGFRas3/EGFRvIII cells, 4TB blocked phosphorylation of
EGFRas3, EGFRvIII, and STAT3, consistent with EGFRvIII phos-
phorylation by EGFR (Figures 5A and 5B). In EGFR/EGFRvIIIas3
cells in the absence of EGF, 4TB potently blocked phosphoryla-
tion of vIIIas3 (likely related to the low intrinsic activity of
EGFRvIII), with no impact on phosphorylation of EGFR. In the
absence of EGF, p-STAT3 was undetectable in these cells. In
the presence of EGF, however, 4TB was unable to block phos-
phorylation of EGFR in EGFR/EGFRvIIIas3 cells with modest
effects on phosphorylation of both EGFRvIIIas3 and p-STAT3.
Notably, in response to EGF, the abundance of p-STAT3 in
EGFR/EGFRvIIIDY5 cells (which contain five nonphosphorylat-
able phenylalanine residues in place of tyrosine in the C terminus
of EGFRvIII; Huang et al., 1997) was much lower than that in
EGFR/EGFRvIII cells. Consistent with the EGFR/EGFRvIIIDY5
result, treatment of LN-229:EGFR/EGFRvIII cells with EGFRvIII
siRNA (Fan and Weiss, 2004) led to decreased phosphorylation
of STAT3 (Figures S5A–S5C).
We used densitometry to quantify the relative levels of
p-STAT3 in LN-229:EGFR/EGFRvIII and NIH 3T3:EGFR/
EGFRvIIIDY5 cells. The relative intensity of p-STAT3 in NIH
3T3:EGFR/EGFRvIII cells (after addition of EGF, 15 min, and
normalization to b-tubulin) was set to 100%. The relative inten-
sity of p-STAT3 dropped to 67% in NIH 3T3:EGFR/EGFRvIIIDY5
cells (Figure 5B). Similarly, in Figure S5, we set the relative in-
tensity of p-STAT3 in LN-229:EGFR/EGFRvIII cells treated
with control siRNA to 100% (after addition of EGF, 15 min,
and normalization to GAPDH). The relative intensity of
p-STAT3 dropped to 59% in response to EGFRvIII siRNA in Fig-
ure S5B and to 55% in Figure S5C, respectively. These data
suggest that phosphorylation of EGFRvIII contributes to STAT
activation.
We next addressed functional effects of selective EGFR and
EGFRvIII inhibition. Consistent with our immunoblot results (Fig-
ures 5A and 5B), treatment of EGFRas3/EGFRvIII cells with 4TB
led to decreases in both proliferation and focus formation,
inducing arrest at G1. In contrast, 4TB had a modest effect on
EGFR/EGFRvIII3as3 or had little effect on EGFR/EGFRvIII cells,
with control EGFRas3 and EGFRvIIIas3 cells showing expected
responses (Figure 5C). Collectively, data in Figure 5 suggest
that EGFR phosphorylates EGFRvIII, and that EGFR and
EGFRvIII converge to phosphorylate STAT proteins, thereby
driving transformation.
Figure 4. EGF Treatment of LN-229:EGFR/EGFRvIII Cells Leads to Prolonged Phosphorylation of EGFR, EGFRvIII, and STAT3/5
The intensity of each protein, quantified by densitometry using Silver Fast Scanner and ImageJ software, is shown below each immunoblot as fold increase
relative to untreated samples (EGF 0 hr or cycloheximide 0 hr) after normalization to GAPDH (bottom panel).
(A) LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, or LN-229:EGFR/EGFRvIII cells were serum-starved for 24 hr and then treated with EGF (50 ng/ml) for the
times shown, prior to harvest, lysis, and analysis by immunoblot using the antisera indicated (top panel).
(B) Cells were grown in 10% FBS and then treated with protein synthesis inhibitor cycloheximide (CHX; 50 mg/ml) for the times shown, prior to harvest, lysis, and
analysis by immunoblot using the antisera indicated (top panel). EGFR is indicated by arrow, whereas EGFRvIII is indicated by arrowhead.
See also Figure S4.
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Cooperation between EGFR and EGFRvIII in GliomaEGFRvIII Is a Substrate for EGFR
EGFR family members signal through allosteric interactions be-
tween monomers, which form an asymmetric dimer. In this
dimer, only one kinase is catalytically activated (the receiver ki-
nase), whereas the other functions as the allosteric activator
(the activator kinase). To determine whether EGFR and EGFRvIIICsignal as an asymmetric heterodimer, we generated receiver-
impaired (I682Q) and activator-impaired (V924R) mutations in
both EGFR and EGFRvIII (Jura et al., 2009). LN-229 and NIH
3T3 cells were stably transduced either with single or double
retroviral constructs as shown in Figure 6A and Figure S6. As
expected, coexpression of EGFRI682Q and EGFRV924R restoredancer Cell 24, 438–449, October 14, 2013 ª2013 Elsevier Inc. 443
Figure 5. Unidirectional Phosphorylation of EGFRvIII by EGFR Correlates with Proliferation and Transformation
(A) Chemical genetic approach: as-allele-selective irreversible inhibitor 4TB did not affect EGFR or EGFRvIII, whereas as-alleles of these kinases (EGFRas3 and
EGFRvIIIas3) were inhibited. EGFRvIIIDY5 represents an allele of EGFRvIII with tyrosine mutated to phenylalanine at codons 992, 1068, 1086, 1148, and 1173.
(B) Immunoblot of NIH 3T3 cells transduced with EGFR, EGFRvIII, EGFRas3, EGFRvIIIas3, EGFR/EGFRvIII, EGFRas3/EGFRvIII, EGFR/EGFRvIIIas3, or EGFR/
EGFRvIIIDY5 is shown. Cells were grown in 10% FBS and treated with or without indicated doses of 4TB for 24 hr. EGF (50 ng/ml) was added to cells 15min before
harvest, and lysates were immunoblotted using the antisera indicated. EGFR is indicated by arrow, whereas EGFRvIII is indicated by arrowhead.
(C) NIH 3T3 cells stably transduced with the indicated retroviral constructs were grown in 10% FBS and treated with or without 0.5 mM of 4TB. Cell proliferation
(WST-1 assay; top panel), flow cytometry (middle panel), and focus formation analyses (bottom panel) are shown. Data aremean ± SDof triplicatemeasurements.
See also Figure S5.
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Cooperation between EGFR and EGFRvIII in Gliomasignificant signaling activity, as compared with cells transduced
individually with either activator-impaired EGFRV924R or receiver-
impaired EGFRI682Q (Figure S6).
To address whether EGFR and EGFRvIII signal as a hetero-
dimer, we next generated EGFRI682Q/EGFRvIIIV924R cells in
which EGFR was an obligate activator and EGFRvIII an obligate
receiver. This combination (as well as the reciprocal EGFRV924R/444 Cancer Cell 24, 438–449, October 14, 2013 ª2013 Elsevier Inc.EGFRvIIII682Q) failed to restore signaling. Coimmunoprecipitation
results also failed to demonstrate a complex between EGFR and
EGFRvIII (Figures S6I and S6J). In contrast, when EGFRwt was
cotransduced with EGFRvIIII682Q or EGFRvIIIV924R, downstream
signaling from EGFRvIII was restored (Figure 6B). Collectively,
these data suggest that EGFR and EGFRvIII signal together
through a heterodimerization-independent mechanism.
Figure 6. EGFRvIII Serves as a Substrate for
EGFR
LN-229 cells stably transduced with retroviral
constructs indicated were serum-starved for 24 hr
and then treated with or without EGF (50 ng/ml) for
15 min prior to harvest. Lysates were immuno-
blotted using the antisera indicated.
(A) Cartoon of receiver-impaired (I682Q) or acti-
vator-impaired (V924R) mutations. Bracketed
numbers correspond to those in (B).
(B) LN-229 cells cotransduced with EGFRI682Q/
EGFRvIIIV924R or with EGFRV92R/EGFRvIIII682Q.
EGFR is indicated by arrow. EGFRvIII is indicated
by arrowhead.
(C) Cartoon of EGFR, EGFR kinase dead (D813N),
EGFRvIII, EGFRvIII kinase dead (D813N), and
combinations. Bracketed numbers correspond to
those in (D).
(D) LN-229 cells cotransduced with EGFRWT,
EGFRD813N, EGFRvIII, EGFRvIIID813N, or combi-
nations. EGFR is indicated by arrow. EGFRvIII is
indicated by arrowhead.
See also Figure S6.
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Cooperation between EGFR and EGFRvIII in GliomaWe next asked whether EGFRvIII could serve as a substrate
for EGFR. Kinase-dead alleles EGFRD813N and EGFRvIIID813N
showed low kinase activities as compared with EGFRwt and
EGFRvIIIwt alleles (Figures 6C and 6D). The EGFRvIIID813N pro-
tein was fully phosphorylated by EGFRwt, whereas EGFRvIIIwt
was unable to phosphorylate kinase-dead EGFRD813N (Figures
6C and 6D). These EGFRvIIID813N data, in conjunction with our
EGFRvIIIDY5 experiments (Figure 5B), suggest EGFRvIII is a sub-
strate of EGFR, with phosphorylation of both EGFR and EGFRvIII
promoting increased and sustained levels of phosphotyrosine inCancer Cell 24, 438–449,the tails of these two RTKs, phosphory-
lating STAT proteins, and driving progres-
sion in glioblastoma.
EGFR and EGFRvIII Cooperate to
Phosphorylate STAT in the Nucleus
To address how EGFR and EGFRvIII
converge on STAT signaling, we analyzed
subcellular fractions. In the absence of
EGF, both EGFR and EGFRvIII were
detected in membrane, cytoplasmic,
and nuclear extracts in LN-229:EGFR,
LN-229:EGFRvIII, and LN-229:EGFR/
EGFRvIII cells (Figure 7A). EGF treatment
of LN-229:EGFR/EGFRvIII cells resulted
in phosphorylation of EGFRvIII in both
cytoplasmic and nuclear protein extracts
(Figure 7A), associated with increased
expression of EGFRvIII in the nucleus
(Figure 7A) and with sustained phosphor-
ylation of STAT3 and STAT5 in the
nucleus. In contrast, EGF treatment of
LN-229:EGFRvIII cells had little effect
on expression of nuclear EGFRvIII,
phosphorylation of EGFRvIII, or STAT
signaling. EGF treatment only transientlyphosphorylated nuclear STAT proteins in LN-229:EGFR cells
and had little effect in LN-229:parental cells (Figure 7A).
We used densitometry to quantify the relative levels of
EGFRvIII phosphorylation in each fraction in LN-229:EGFR/
EGFRvIII cells. The relative intensity of p-EGFRvIII in membrane
fractions without EGF stimulation was set to 100% after normal-
ization to b-tubulin from membrane fractions. The relative inten-
sity dropped to 86%after EGF stimulation for 15min, and to 90%
after EGF stimulation for 6 hr. Again, we set the relative intensity
of p-EGFRvIII in cytoplasm fractions without EGF stimulation toOctober 14, 2013 ª2013 Elsevier Inc. 445
Figure 7. EGFR and EGFRvIII Cooperate to
Active STAT in the Nucleus
(A) LN-229:parent, LN-229:EGFR, LN-229:
EGFRvIII, or LN-229:EGFR/EGFRvIII cells were
serum-starved for 24 hr and then treated with EGF
(50 ng/ml) for the times shown. Samples were
harvested; subject to subcellular fractionation to
obtainmembrane (M), cytoplasmic (C), and nuclear
(N) extracts; and analyzed by immunoblot using the
antisera indicated. EGFR is indicated by arrow,
whereas EGFRvIII is indicated by arrowhead.
(B) LN-229:EGFRvIII, LN-229:EGFRvIIIdNLS, LN-
229:EGFR/EGFRvIIIdNLS, or LN-229:EGFR/
EGFRvIII were serum-starved for 24 hr and then
treated with EGF (50 ng/ml) for 0 and 15 min.
Whole-cell lysates or nuclear extracts were
analyzed by immunoblot using the antisera indi-
cated.
(C) LN229:parent, LN-229:EGFR, LN-229:
EGFRvIII, or LN-229:EGFR/EGFRvIII cells were
serum-starved for 24 hr, treated with EGF
(50 ng/ml) for 0 and 15 min, and fractionated to
obtain nuclear extracts. Nuclear STAT3 was
immunoprecipitated using a mouse monoclonal
STAT3 antibody, and immunoprecipitates were
analyzed by immunoblot to detect EGFR and
EGFRvIII (using a rabbit polyclonal EGFR antibody,
which recognizes both EGFR and EGFRvIII). Effi-
cacy of subcellular fractionation in (A), (B), and (C)
is indicated bymembrane and cytoplasmicmarker
protein b-tubulin, cytoplasmic marker protein
GAPDH, and nuclear marker protein Lamin B1.
See also Figure S7.
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tions. The relative intensity then increased to 353% after EGF
stimulation for 15 min, and to 340% after EGF stimulation for
6 hr. In nuclear fractions, we again set the relative intensity of
p-EGFRvIII in nuclear fractions without EGF to 100% after
normalization to Lamin B1 from nuclear fractions. The relative in-
tensity increased to 126% after EGF stimulation for 15 min, and
to 142% after EGF stimulation for 6 hr. These data suggest that
EGF treatment of EGFR/EGFRvIII cells increased phosphoryla-
tion of EGFRvIII in cytoplasmic and nuclear fractions, but not in
membrane fractions (Figure 7A).
To clarify whether EGFRvIII undergoes nuclear translocation
to phosphorylate STAT proteins, we transfected LN-229 cells
with EGFRvIIIdNLS, an allele of EGFRvIII defective for nuclear
entry (Lo et al., 2010), and established stable LN-229:
EGFRvIIIdNLS and LN-229:EGFR/EGFRvIIIdNLS cell lines. LN-
229:EGFRvIIIdNLS and LN-229:EGFR/EGFRvIIIdNLS cells
expressed levels of EGFRvIII equivalent to those in LN-
229:EGFRvIII and LN-229:EGFR/EGFRvIII cells. EGF-treated
LN-229:EGFR/EGFRvIII cells had higher levels of phosphory-446 Cancer Cell 24, 438–449, October 14, 2013 ª2013 Elsevier Inc.lated STAT proteins as compared to
levels in LN-229:EGFR/EGFRvIIIdNLS
cells (Figure 7B). Consistent with our
immunoblot results using whole-cell
lysates (Figure 7B top panel) EGF treat-
ment of LN-229:EGFR/EGFRvIIIdNLS
cells resulted in decreased phosphoryla-tion of STAT in the nuclear fraction (Figure 7B bottom panel).
These data suggest that EGF treatment of EGFR/EGFRvIII cells
enhances both nuclear transport of EGFRvIII and phosphoryla-
tion of STAT in the nucleus.
We next asked whether nuclear EGFR and EGFRvIII could
complex with STAT3 in the nucleus. Nuclear STAT3 was immu-
noprecipitated and immunoblots analyzed to detect nuclear
EGFR and EGFRvIII (Figure 7C). Nuclear lysates, whole-cell
lysates (input), and nuclear immunoprecipitations are shown
in Figure 7C. In LN-229:EGFR/EGFRvIII cells, the levels of
nuclear EGFRvIII complexed to STAT3 were enhanced
following 15 min of EGF treatment. In contrast, EGF treatment
had little effect on the EGFRvIII/STAT3 complex in LN-229:vIII
cells. As expected, mouse IgG did not pull down STAT3 or
EGFR/EGFRvIII. Collectively, these data suggest that EGFR
phosphorylates EGFRvIII, leading to increased nuclear translo-
cation of EGFRvIII and enhanced binding of EGFRvIII to STAT3
in the nucleus.
High STAT3 activity may contribute to resistance of GBM pa-
tients to EGFR inhibitors (Mellinghoff et al., 2005; Reardon et al.,
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EGFR in glioma? To partially address this issue, we showed
that cells treated with the STAT3 tool inhibitor Stattic in combina-
tion with the EGFR inhibitor erlotinib showed differential induc-
tion of apoptosis (Figure S7). Baseline levels of apoptosis differ
among the four lines, consistent with EGFR and EGFRvIII inde-
pendently modestly blocking basal apoptosis, with a more
prominent effect of EGFR/EGFRvIII in combination. Thus, LN-
229:EGFR/EGFRvIII cells at baseline showed 2.1% apoptosis,
compared to 44.8% in response to Stattic and erlotinib (21-
fold change). LN-229:EGFRvIII cells at baseline showed 3.4%
apoptosis, compared to 46.9% in response to Stattic and erloti-
nib (14-fold change). By comparison, LN-229:EGFR cells at
baseline showed 4.3% apoptosis, compared to 40.6% in
response to Stattic and erlotinib (9-fold change), while LN-
229:parent cells at baseline showed 6.8% apoptosis, compared
to 42.1% in response to Stattic and erlotinib (6-fold change).
These data suggest cooperative blockade of EGFR and STAT3
as a developmental therapeutic strategy in EGFR/EGFRvIII
coamplified glioma.
DISCUSSION
Amplification and overexpression of EGFR represent striking
features of primary glioblastoma, with frequent coamplification
of EGFR and its deletion mutant, EGFRvIII (Huang et al., 1997;
Sugawa et al., 1990; Wong et al., 1992). Using immunofluores-
cence double staining with EGFR- and EGFRvIII-specific
antibodies, we demonstrate that EGFR and EGFRvIII colocalize
within individual tumor cells in glioblastoma. We further high-
light cooperation between EGFR and EGFRvIII in transforma-
tion in vivo, with cell-based experiments showing that EGF
treatment of cells expressing both EGFR and EGFRvIII resulted
in phosphorylation of both kinases. This result was unexpected
because EGFRvIII is unable to bind or be activated in response
to EGF. Using chemical genetic approaches, we found that
EGFR promoted unidirectional EGFRvIII signaling in glioblas-
toma cells, driving further phosphorylation of STAT proteins
and enhanced malignancy. It is intriguing that enhanced
STAT signaling is so selectively affected by EGFR/EGFRvIII
crosstalk, whereas signaling through PI3K and MAPK is less
prominently affected. In addition, STAT signaling has been
suggested to feature prominently in glioma stem cells (Gurya-
nova et al., 2011). That rare cells within GBM tumors coamplify
EGFR and EGFRvIII and phosphorylate STAT3 could be consis-
tent with a role for STAT3 activation within the stem cell
compartment of GBM.
How does EGFR activate EGFRvIII? Whereas others have
demonstrated physical binding of these two kinases, our coim-
munoprecipitation experiments failed to demonstrate this inter-
action. We were similarly unable to reconstitute signaling in
a heterodimeric complex where EGFR was an obligate
allosteric activator and EGFRvIII an obligate receiver. Kinase-
dead EGFRvIII was readily phosphorylated by EGFR, suggest-
ing EGFRvIII as a substrate of EGFR. Phosphorylation of both
EGFR and EGFRvIII were required to fully phosphorylate
STAT proteins. EGFR, when expressed alone, led to lower level
and shorter duration of STAT phosphorylation, as compared to
levels and duration observed in cells coexpressing both EGFRCand EGFRvIII. Further, coexpression of EGFR with EGFRvIIIDY5,
a mutant in which tyrosines in the tail of EGFRvIII were re-
placed with phenylalanines, blunted phosphorylation of
STAT3 protein.
Analysis of human glioblastoma tumors demonstrated align-
ment among EGFR, EGFRvIII, and STAT signaling in tumors,
supporting a model in which EGFR activation of EGFRvIII leads
to transphosphorylation of both kinases, converging on STAT
signaling. Using subcellular fractionation, we further demon-
strated that EGFR phosphorylation of EGFRvIII led to nuclear
transport of EGFRvIII and enhanced the formation of a complex
between EGFRvIII and STAT3 in the nucleus. These data suggest
that EGFR and EGFRvIII coordinately drive enhanced and pro-
longed STAT activity in the nucleus. It remains possible, how-
ever, that very high levels of EGFR could subserve this role
even in the absence of EGFRvIII.
In this study, we identify an EGFR-EGFRvIII-STAT signaling
axis in a subset of glioblastomas that coamplify EGFR and
EGFRvIII within individual tumor cells. Given that coexpressed
EGFR and EGFRvIII and high levels of STAT signalingmay confer
both more aggressive behavior in glioblastoma (Abou-Ghazal
et al., 2008; Birner et al., 2010; Shinojima et al., 2003), our find-
ings suggest targeting EGFR in conjunction with STAT signaling
as a therapeutic strategy for patients with EGFRvIII-positive
glioblastoma.
EXPERIMENTAL PROCEDURES
Tumor Samples
Primary tumor samples were obtained in accordance with research ethics
board approval from UCSF and the Heinrich Heine University. Informed con-
sent was obtained from all UCSF patients. Archival samples from Du¨sseldorf
were investigated in an anonymized manner, approved by the ethics commit-
tee of the Medical Faculty of Heinrich Heine University.
Construction of EGFR and EGFRvIII Mutants
Retroviral-based pWLZ-hygro-EGFR-as3 was described previously (Blair
et al., 2007). pWLZ-hygro-EGFRas3 plasmid was digested with BstXI and
ligated into a similarly digested pLRNL-neo-EGFRvIII plasmid, generating
retroviral-based pLRNL-neo-EGFRvIII-as3, an analog-sensitive allele of
EGFRvIII. pLRNL-neo-EGFRvIIIDY5 (Johns et al., 2007) and pCMV-tag5A-
EGFRvIIIdNLS (Lo et al., 2010) were generously provided by Drs. Frank Furnari
and Hui-Wen Lo, respectively. Point mutations (I682Q and V924R) were engi-
neered into the pWLZ-hygro-EGFR or into the pLRNL-neo-EGFRvIII by site-
directed mutagenesis (QuickChange Mutagenesis kit, Stratagene). All primer
sequences are in Thiel and Carpenter (2007). Point mutation pcDNA-neo-
EGFR (D813N) plasmid was from Natalia Jura, UCSF; digested with BstXI;
ligated into a similarly digested vector; and used to generate either pWLZ-
hygro-EGFR (D813N) or pLRNL-neo-EGFRvIII (D813N). All mutants were
sequence validated.
Cell Lines, Reagents, Transfection, and Transduction
Human glioma cell lines LN-229 and U87MGwere obtained from the Brain Tu-
mor Research Center at UCSF. NIH 3T3 mouse fibroblasts were from ATCC.
These and derivate lines were grown in 0.5% or 10% FBS. To generate retro-
virus, the packaging cell line 293T was cotransfected with plasmids gag/pol
and VSVg, using Effectene-transfection reagent (QIAGEN). High-titer virus
was collected at 48 hr and used to infect cells as previously described (Fan
et al., 2007). pCMV-tag5A-EGFRvIIIdNLS plasmid was generously provided
by Dr. Hui-Wen Lo, Duke University, and transfected into LN-229:parent or
LN-229:EGFR cells. Transfected and transduced cells were selected as pools
with G418 (800 mg/ml) or hygromycin (500 mg/ml) for 2 weeks. EGF was from
Roche. Cyclohexmide and Stattic were from Sigma. 4TB [N-(4-(4-tert-butyl-
phenylamino)quinazolin-6-yl)] acrylamidewere synthesized as described (Blair
et al., 2007).ancer Cell 24, 438–449, October 14, 2013 ª2013 Elsevier Inc. 447
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Immunohistochemical staining was performed by the UCSF Neurosurgery
Tissue Core. Paraffin-embedded sections (5 mm) of human GBM were immu-
nostained on the Benchmark XT automated stainer (Ventana Medical Sys-
tem). Antibodies were detected with the Ventana iVIEW DAB detection kit
(yielding a brown reaction product). The EGFR antibody utilized in this study
was a mouse monoclonal antibody obtained from Ventana 790-2988 (clone
3C6), which recognizes the extracellular domain of both full-length and the
EGFRvIII variant of EGFR and was supplied as part of an FDA-validated clin-
ical diagnostic kit for EGFR abundance, used clinically to assess EGFR sta-
tus. The EGFRvIII mouse monoclonal antibody was from Duke University
(L8A4). Slides were counterstained with hematoxylin. Immunostaining results
were graded in a semiquantitative manner by determining the intensity of
staining of each section and grading from 0 (no staining), 1 (1–25% immuno-
reactivity of cells), 2 (26–75% immunoreactivity), to 3 (>75% immuno-
reactivity). Human glioblastoma tissue samples were routinely fixed in 4%
buffered formaldehyde and embedded in paraffin. Five-micron-thick tissue
sections were deparaffinized in xylene and rehydrated over a graded ethanol
series. For antigen retrieval, rehydrated sections were treated in 10 mM cit-
rate buffer at pH 6.0 (for EGFRvIII and p-STAT3) or at pH 9.0 (for EGFR) for
20 min in a steamer. Sections were immunostained with antibodies against
EGFR (mouse monoclonal DAK-H1-WT; Dako; diluted 1:200), EGFRvIII (rabbit
polyclonal 6549; Celldex; diluted 1:5000), or p-STAT3 (Tyr705) (rabbit mono-
clonal antibody D3A7 or mouse monoclonal antibody 3E2; Cell Signaling;
each diluted 1:50). Immunohistochemistry was performed on the Dako Autos-
tainer Plus automated slide-processing system using the Ultravision LP Large
Volume Detection System HRP Polymer (Thermo Scientific) for detection of
antibody binding according to the manufacturer’s protocol. 3,3-Diaminoben-
zidine was used as substrate for the peroxidase reaction. Slides were coun-
terstained with hemalum, dehydrated, and mounted in DePeX (Serva)
mounting medium.
Double-Immunofluorescence Analyses
Glioma cells grown as monolayer cultures on chamber slides were fixed with
methanol. Formalin-fixed paraffin sections from primary tumor tissues were
deparaffinized in xylene and rehydrated over a graded ethanol series, followed
by treatment in 10 mM citrate buffer at pH 6.0 for 20 min in a steamer for an-
tigen retrieval. Rehydrated fixed cells and tissue sections were blocked 5 min
with Ultra V Block (Thermo Scientific) and incubated overnight at 4C with pri-
mary antibodies against EGFR (mouse monoclonal DAK-H1-WT; Dako) and
EGFRvIII (rabbit polyclonal 6549; Celldex) diluted 1:50. Additional double-la-
beling experiments were performed with antibodies against EGFR and
p-STAT3 (Tyr705) antibody (rabbit monoclonal antibody D3A7; Cell Signaling)
or antibodies against EGFRvIII and p-STAT3 (Tyr705) antibody (mouse mono-
clonal antibody 3E2; Cell Signaling). Three washing steps were followed by
incubation at room temperature for 1 hr with Alexa Fluor 488/594 secondary
antibodies (Invitrogen) diluted 1:500. Following repeated washing, stained
sections and cells were mounted in ProLong Gold antifade reagent (Invitrogen)
with DAPI.
In Vitro and In Vivo Growth Assays
We used the Cell Transformation Detection Assay kit (Millipore) to evaluate
colony formation on soft agar. Briefly, plates were precoated with 0.7%
agarose as the bottom layer. Cells were seeded at a density of 1 3 104 cells
per six wells in triplicate for each cell line and cultured in 0.35% agarose
as the top layer in DMEM (without phenol red) plus 10% FBS at 37C
for 3 weeks. The cells were kept wet by adding a small amount of culture
media. EGF (50 ng/ml) was added every 5 days. Colonies were stained
overnight at 37C (Cell Transformation Detection Assay kit; Millipore). Colony
numbers in the entire well were counted under the microscope. For nude
mice, LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, and LN-229:EGFR/
EGFRvIII cells (106) were injected subcutaneously just caudal to the left
forelimb in 4- to 6-week-old BALB/c nu/nu mice (Harlan Sprague-Dawley).
Tumor diameters were measured with calipers at 7-day intervals, and
volumes calculated from five mice per data point (mm3 = width2 3 length /
2). UCSF’s Institutional Animal Care and Use Committee approved all exper-
iments. Each value represents mean tumor volume ± SE obtained from five
mice.448 Cancer Cell 24, 438–449, October 14, 2013 ª2013 Elsevier Inc.Immunoblotting
Membranes were blotted with p-EGFRY845, p-EGFRY992, p-EGFRY1045,
p-EGFRY1068, p-AKTS473, AKT, p-S6 ribosomal proteinS235/236, S6 ribosomal
protein, p-ERKT202/Y204, p-STAT3 (Tyr705), STAT3, STAT5, Lamin B1 (all
from Cell Signaling), p-EGFRY1173, EGFR, ERK, normal mouse IgG (Santa
Cruz Biotechnology), p-STAT5Y694 (BD Transduction Laboratories), GAPDH,
or b-tubulin (Upstate Biotechnology). Bound antibodies were detected with
HRP-linked antimouse or antirabbit IgG (Calbiochem), followed by ECL
(Amersham).
Subcellular Fractionation and Immunoprecipitation
For multicompartmental fractionation of cells we used the subcellular protein
fractionation kit (Thermo Scientific Pierce) according to the manufacturer’s in-
structions. For immunoprecipitation, 200 mg nuclear protein were incubated
with 1 mg anti-STAT3 mouse monoclonal antibody (Cell Signaling) or control
mouse IgG at 4C overnight with gentle agitation. Following addition of 20 ml
protein G-agarose and incubation for 1 hr at 4C, the immunocomplexes
were pelleted, washed for multiple cycles at 4C, and then subjected to
SDS-PAGE and western blotting analysis probing for EGFR (rabbit antibody
that recognizes both EGFR and EGFRvIII; Santa Cruz Biotechnology).
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